NEURIMP
Financiado
Novel combination of biopolymers and manufacturing technologies for production o...
Novel combination of biopolymers and manufacturing technologies for production of a peripheral nerve implant containing an internal aligned channels array
Peripheral nerves are basic communication structures guiding motor and sensitive information from CNS to effector or receptor units. Severe nerve injuries include axon bundles section and Schawnn cells destruction, which results i...
Peripheral nerves are basic communication structures guiding motor and sensitive information from CNS to effector or receptor units. Severe nerve injuries include axon bundles section and Schawnn cells destruction, which results in loss of motion control and sensorial perception. After the lesion, cells present in damaged nerves activate spontaneously self-regeneration programs that might facilitate further treatment. Nerve autograft is the gold standard surgical intervention that demands autologous tissue extraction and corresponding function loss. The goal of the project is the validation of biomaterials structural plasticity and those compatible manufacturing technologies that will enable the generation of a tubular structure containing an intraluminal microstructure based on an array of aligned channels or fibers. The regenerative properties of this prototype will be also validated in vivo in a sciatic nerve section animal model. This project proposal will take advantage of partners’ experience in the design of medical devices composed of natural and synthetic biomaterials and in scaled-up production mechanization technologies for the generation of the most effective peripheral nerve implant.
ver más
Línea de financiación: concedida
El organismo FP7 notifico la concesión del proyecto el día 2017-12-31
Presupuesto
El presupuesto total del proyecto asciende a
4M€
Líder del proyecto
FUNDACION TEKNIKER
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
2-3
21M
Perfil tecnológico
TRL
2-3
21M
N.D. |
Participante
N.D. |
Participante
N.D. |
Participante